Article
A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications.
All News
Article
Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of t
Article
Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.
Article
Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
Article
Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon, drive systemic lupus erythematosus and cutaneous lupus erythematosus. A recent comprehensive review synthesizes the available data on pDCs, and, importantly, what we still don't know.
Dr. John Cush
Tweet
Increased Polypharmacy in SLE Patients
A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications.
https://t.co/3Mo3O8Ra04 https://t.co/zRS8TmFvvf
Dr. John Cush
Tweet
RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's
A small pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease.
https://t.co/eeyhso0WJ6 https://t.co/ZGWOOtf92E
Dr. John Cush
Tweet
In the cross-sectional study of US SLE patients, what was the most common drug class driving polypharmacy beyond SLE medications? Test your knowledge in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/ox4rGp04WH
Dr. John Cush
Tweet
LRA Awards for Immune Resetting Therapies in Lupus
LRA, the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of the Lupus Research Alliance-Genentech Award on Immune Resetting https://t.co/eDAq17lhM0
Dr. John Cush
Tweet
Hopkins study of HCQ in discoid lupus (DLE) - 5 yr outcomes of 106 adult DLE; those on HCQ had less hyperlipidemia (HL), PAD, angina, & CAD. Parallel TriNetX study showed HCQ assoc w/ signif less HTN, HL, DM, CAD, & CVA. https://t.co/yX7FkGCnvR https://t.co/oddq68FYeE
Dr. John Cush
Tweet
Trends and Innovations in Lupus Nephritis Clinical Trials
Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.
This systematic review of was informed by 200 interventional pharmacological trials https://t.co/fUTIMhMAis
Dr. John Cush
Tweet
Population cohort study of pregnancies from UK Clinical Practice Research Datalink, 5.2 million pregnancies, ~2.5 mill births. Incr risk for miscarriage in Sjögrens (aRR 1.66), C-sect in IBD (1.27), SGA in SLE (2.45), preterm birth in RA (1.53), stillbirth in SLE (1.82) & more https://t.co/IjtRTE2t78
Dr. John Cush
Tweet
30 yr Retrospective study of 1216 SLE hospitalizations in Barcelona - SLE flares & infections were most frequent. Hosp for infections signif. increased & in last 5yrs, exceeded Dz flares (34% vs. 26%). Younger pts had more flare hosp; older more infx hosp. Over time infx have https://t.co/TkUiXaoL1R
Dr. John Cush
Tweet
Case-control study of 349 autoimmune (ARD) pts (SLE, RA, SSc) & serum assays for anti-neutrophil extracellular trap (aNET)Abs. aNET in 37% SLE assoc w/ APS (OR 3.4) & arterial thrombosis (OR 5.5). aNET in 40% RA assoc w/ ACPA+ (p=0.049) https://t.co/QwvmLAVmg7 https://t.co/VJ7JV5fcZE
Dr. John Cush
Tweet
Canada’s Drug Agency (CDA-AMC) has recommended Gazyva (obinutuzumab) for public reimbursement. This recommendation is for the treatment of adult patients with active lupus nephritis who are receiving standard therapy https://t.co/TC1MVAShdC https://t.co/flXVmLwGtW
Dr. John Cush
Tweet
Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon (IFN-I), drive systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). A recent comprehensive review synthesizes the https://t.co/VaE295a2Ep
Dr. John Cush
Tweet
True or False: In a Japanese study of refractory neuropsychiatric SLE, rituximab led to significant improvement in the majority of patients treated. See if you got it right at https://t.co/3F1h89Qrtw https://t.co/vx0ILsZ3WF
Dr. John Cush
Tweet
Fatigue in SLE
An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients.
https://t.co/63JVDUwu88 https://t.co/3dPOThMbMD
Dr. John Cush
Tweet
HCQ: 5 mg/kg/day Is Only the Starting Point
HCQ is one of the most important drugs in rheumatology, especially for SLE. It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival. Yet many clinicians still prescribe HCQ as if https://t.co/Fwr92tuZf2
Dr. John Cush
Tweet
Does RTX work in CNS lupus? Japanese experience in 17 refractory NP-SLE pts Rx w/ RTX - 16/17 had significant improve. & 1 partial improvement -- none had NP-SLE relapse. Two died during COVID> https://t.co/GpCgpSxn37 https://t.co/PMz05MHBhj
